INCORPORATION BY REFERENCE
This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512,
333-213412, 333-214843, 333-216883, 333-228576,
333-254101, 333-261550, 333-270088 and 333-277519) and Form F-3 (Registration Numbers 333-209336, 333-211511, 333-216882,
333-223134, 333-225284 and 333-256571) of Ascendis Pharma A/S (the “Company” or “Ascendis”) (including any
prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
On August 12, 2024, the Company announced that the U.S. Food & Drug Administration (the “FDA”) has approved YORVIPATH® (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults. YORVIPATH is a prodrug of parathyroid hormone (PTH
[1-34]), administered once daily, designed to provide continuous exposure to released PTH over the 24-hour dosing period. The Company is completing manufacturing of
commercial product for the U.S. market and anticipates initial supply will be available in the first quarter of 2025. In addition, the Company plans to request FDA approval to commercialize existing manufactured product, which, if approved, could be
introduced in the U.S. in the fourth quarter of 2024.
Forward-Looking Statements
This report contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts,
included in this report regarding the Company’s future operations, plans and objectives are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the Company’s expectations
regarding the timing of initial commercial supply of YORVIPATH for the U.S. market and the Company’s plans to request FDA approval to commercialize existing manufactured product and the potential timing of introduction in the U.S., if such
request is approved. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking
statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially
from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products; unforeseen safety or efficacy results in Ascendis’
development programs or approved products; unforeseen expenses related to commercialization of any Ascendis products; unforeseen expenses related to Ascendis’ development programs; delays in the development of its programs related to
manufacturing, regulatory requirements or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and
business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see
Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 7, 2024 and Ascendis’ other future reports filed with, or submitted
to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume
any obligation to update any forward-looking statements, except as required by law.